Exenatide in type 2 diabetes: Treatment effects in clinical studies and animal study data

International Journal of Clinical Practice

Volumn 60, Issue 12, 2006, Pages 1654-1661

  Gallwitz, Baptist ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Exenatide; Glucagon like peptide 1; Incretin mimetics; Incretins; Type 2 diabetes

Indexed keywords

CJC 1131; EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INCRETIN; INSULIN; INSULIN GLARGINE; JANUVIA; LIRAGLUTIDE; LONG ACTING DRUG; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG; VILDAGLIPTIN;

CELL FUNCTION; CELL VOLUME; CLINICAL STUDY; CLINICAL TRIAL; DIABETES CONTROL; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; GASTROINTESTINAL SYMPTOM; HEMOGLOBIN DETERMINATION; HORMONE ACTION; HUMAN; HYPOGLYCEMIA; INSULINOMA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION;

ANIMALS; CLINICAL TRIALS; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; LIZARDS; PEPTIDES; RODENTIA; VENOMS;

EID: 33751009626     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01196.x     Document Type: Review

References (30)

1. Creutzfeldt W. The incretin concept today. Diabetologia 1979; 16: 75-85.
2. Creutzfeldt W. Entero-insular axis and diabetes mellitus. Horm Metab Res Suppl 1992; 26: 13-8.
3. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301-7.
4. Nauck MA, Meier JJ. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept 2005; 128: 135-48.
5. Gallwitz B. Therapies for the treatment of type 2 diabetes mellitus based on incretin action. Minerva Endocrinol 2006; 31: 133-47.
6. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study. Lancet 2002, 359: 824-30.
7. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153-65.
8. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993; 214: 829-35.
9. Holst JJ. Glucagon-like peptide-1: From extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 2006; 49: 253-60.
10. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992; 267: 7402-5.
11. Goke R, Fehmann HC, Linn T et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993; 268: 19650-5.
12. Kolterman OG, Kim DD, Shen L et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005; 62: 173-81.
13. Fineman MS, Bicsak TA, Shen LZ et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003; 26: 2370-7.
14. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-35.
15. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-100.
16. Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-91.
17. Ratner RE, Maggs D, Nielsen LL et al. Long-term effects of exenatide therapy over 82weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006; 8: 419-28.
18. Blonde L, Klein EJ, Han J et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006; 8: 436-47.
19. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial. Ann Intern Med 2005; 143: 559-69.
20. Fehse F, Trautmann M, Holst JJ et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 5991-7.
21. Kolterman OG, Buse JB, Fineman MS et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3082-9.
22. Taylor K, Kim D, Nielsen LL, Aisporna M, Baron AD, Fineman MS. Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes. Horm Metab Res 2005; 37: 627-32.
23. Tourrel C, Bailbe D, Meile MJ, Kergoat M, Portha B. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 2001; 50: 1562-70.
24. Baggio L, Adatia F, Bock T, Brubaker PL, Drucker DJ. Sustained expression of exendin-4 does not perturb glucose homeostasis, beta-cell mass, or food intake in metallothionein-preproexendin transgenic mice. J Biol Chem 2000; 275: 34471-7.
25. Brubaker PL, Drucker DJ. Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 2004; 145: 2653-59.
26. Farilla L, Bulotta A, Hirshberg B et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003; 144: 5149-58.
27. Wang Q, Li L, Xu E, Wong V, Rhodes C, Brubaker PL. Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia 2004; 47: 478-87.
28. Ding X, Saxena NK, Lin S, Gupta N, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 2006; 43: 173-81.
29. Gedulin BR, Smith P, Prickett KS et al. Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats. Diabetologia 2005; 48: 1380-5.
30. Kim D, Macconell L, Zhuang D et al. Safety and effects of a once-weekly, long-acting release formulation of exenatide over 15weeks in patients with type 2 diabetes. Diabetes 2006; 55 (Suppl. 1): A116.